Targeting Genome Stability in Melanoma—A New Approach to an Old Field
Despite recent groundbreaking advances in the treatment of cutaneous melanoma, it remains one of the most treatment-resistant malignancies. Due to resistance to conventional chemotherapy, the therapeutic focus has shifted away from aiming at melanoma genome stability in favor of molecularly targeted...
Main Authors: | Marta Osrodek, Michal Wozniak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/7/3485 |
Similar Items
-
MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
by: Maria Letizia Motti, et al.
Published: (2020-06-01) -
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
by: Claudia Trojaniello, et al.
Published: (2021-06-01) -
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
by: Andrew Hantel, et al.
Published: (2018-07-01) -
Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment
by: Juliane Weilandt, et al.
Published: (2020-03-01) -
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
by: Sonja C. S. Simon, et al.
Published: (2020-01-01)